Sbir phase i topic 354- a non-invasive approach to assess mutation load in tumors for treatment with checkpoint inhibitors
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201600005C
- Awardee
-
Personal Genome Diagnostics Inc. UEI F2TMFXLXHPU7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $222,994
Award facts
- Opportunity
-
- PHS20161 Solicitation number
- Contract value 100% obligated
- $222,994.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Baltimore, MD 21224, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $222,994 |
About this award
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Personal Genome Diagnostics Inc., a for-profit company that provides molecular tissue testing services to federal agencies. The contract has a ceiling value of $222,994.00 and is a firm-fixed-price definitive contract for the development of a non-invasive approach to assess mutation load in tumors for treatment with checkpoint inhibitors. The contract has a period of performance from September 19, 2016, to October 18, 2018, and is designated as a Total Small Business set-aside. Personal Genome Diagnostics has been awarded several small purchase orders from the Department of Veterans Affairs for molecular tissue testing and DNA testing services, but this SBIR Phase I contract appears to be the company's largest federal award to date.
Quick answers
Who was awarded contract HHSN261201600005C?
HHSN261201600005C was awarded to Personal Genome Diagnostics Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.
How much is contract HHSN261201600005C worth?
The government has obligated $222,994 on HHSN261201600005C.
Was contract HHSN261201600005C competed?
The extent of competition for HHSN261201600005C was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award